Carboplatin-cyclophosphamide Combined With Atezolizumab
This is a single centre, 3+3, dose finding, open label, phase 1b clinical study of carboplatin and cyclophosphamide, in combination with atezolizumab.
Breast Cancer|Cervix Cancer|Ovarian Cancer|Endometrial Cancer
DRUG: carbplatin, cyclophophamide, atezolizumab
Toxicity; Incidence of toxicity, graded according to National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 4.03, Adverse events will be graded according to NCI Common Toxicity Criteria version 4.03, up to 30 days after end of treatment
Overall Response Rate, Tumor response will be measured according to the RECIST 1.1 criteria, assessed up to 120 months
The starting dose is carboplatin AUC 5mg/ml\*min, cyclophosphamide 600mg/m2 and atezolizumab 840 mg, all administered intravenously. One cycle is 28 days. On day 1 carboplatin, cyclophosphamide and atezolizumab will be administered. On day 15 atezolizumab only will be administered. Patients will be treated until loss of clinical benefit, unacceptable toxicities, or withdrawal of consent. It is expected that 6-12 patients will be enrolled, depending on safety issues observed.